# Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

> **NCT06971939** · PHASE4 · RECRUITING · sponsor: **Neurotech Pharmaceuticals** · enrollment: 285 (estimated)

## Conditions studied

- Macular Telangiectasia Type 2 (MacTel)

## Interventions

- **COMBINATION_PRODUCT:** NT-501/revakinagene taroretcel-lwey

## Key facts

- **NCT ID:** NCT06971939
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-21
- **Primary completion:** 2032-01-15
- **Final completion:** 2032-01-15
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06971939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06971939, "Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06971939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*